Camphor
Active ingredient
Sold as Menticam · Milagroso · Chest Rub · Equate Rub · Joint Therapy
- Drug class
- -
- Availability
- Over-the-counter
- Routes
- Topical, Percutaneous, Transdermal, Respiratory (Inhalation), Rectal
- Markets covered
- 3
- Products on record
- 70
- FDA reports (12 mo)
- 147
Overview
Plain-language summary, compiled from the cited regulatory records
Camphor is an active ingredient used for the temporary relief of minor aches and pains of muscles and joints. These conditions may include those associated with simple backache, arthritis, strains, bruises, and sprains [1].
This ingredient is available in various products on the market. Examples include Dragon Pain Relieving Balm, Equate Rub, and CVS Health Medicated Chest Rub [1].
In the past 12 months, there have been 147 adverse event reports associated with camphor [2]. The most frequently reported adverse events include diarrhea, the drug being ineffective, fatigue, nausea, and arthralgia [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 61 | April 27, 2026 |
| GB United Kingdom | MHRA | 5 | April 24, 2026 |
| CA Canada | Health Canada | 4 | March 22, 2025 |
USUnited States· FDA
61 products
Uses
Uses For the temporary relief of minor aches and pains of muscles and joints associated with simple backache arthritis strains bruises sprains
How to take
GBUnited Kingdom· MHRA
5 products
Uses
Tiger Balm White is indicated in adults and children aged 2 years and older:
For the symptomatic relief of minor muscular aches and pains. Do not use on children under 2 years.
Tiger Balm White is indicated in adults only:
For the treatment of tension headache..
How to take
CACanada· Health Canada
4 products
4 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Sources & citations
- [1]FDA DailyMed · 002997d0-3176-39… · revised November 24, 2025 [PDF]
- [2]MHRA (UK) · PL028550235 · revised June 21, 2024
- [3]Health Canada (DPD) · 00299561 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.